Key Points
- CFO Hunter Smith sold 4,385 shares at an average price of $101.26 for a total of $444,025.10, trimming his stake by 3.82% to 110,512 shares valued at about $11.19 million.
- RYTM shares fell about 3.0% to $100.05 on the reported session with 170,540 shares changing hands; the company has a market cap of $6.68 billion and a 12‑month range of $45.90–$122.20.
- Analyst sentiment is positive, with a consensus "Moderate Buy" and an average target of $131.50 — multiple firms have issued overweight/outperform ratings and raised price targets into the $145–$167 range.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CFO Hunter Smith sold 3,569 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $101.38, for a total value of $361,825.22. Following the sale, the chief financial officer directly owned 114,897 shares in the company, valued at $11,648,257.86. The trade was a 3.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Rhythm Pharmaceuticals Price Performance
Shares of NASDAQ:RYTM traded down $2.84 during trading on Friday, hitting $100.32. The company had a trading volume of 193,054 shares, compared to its average volume of 630,294. The stock has a market cap of $6.70 billion, a price-to-earnings ratio of -32.33 and a beta of 2.00. The company has a fifty day simple moving average of $105.69 and a two-hundred day simple moving average of $103.23. Rhythm Pharmaceuticals, Inc. has a one year low of $45.90 and a one year high of $122.20.
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the stock. Xponance LLC boosted its position in Rhythm Pharmaceuticals by 2.6% in the 4th quarter. Xponance LLC now owns 4,269 shares of the company's stock valued at $457,000 after buying an additional 107 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in Rhythm Pharmaceuticals by 4.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company's stock worth $259,000 after purchasing an additional 110 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Rhythm Pharmaceuticals by 39.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 399 shares of the company's stock worth $43,000 after purchasing an additional 113 shares during the period. Captrust Financial Advisors raised its position in Rhythm Pharmaceuticals by 0.7% during the 2nd quarter. Captrust Financial Advisors now owns 17,471 shares of the company's stock valued at $1,104,000 after purchasing an additional 114 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Rhythm Pharmaceuticals by 48.6% in the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company's stock worth $39,000 after buying an additional 118 shares during the period.
Analyst Ratings Changes
A number of research analysts have weighed in on RYTM shares. Morgan Stanley reiterated an "overweight" rating and set a $150.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. UBS Group restated a "buy" rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, December 17th. Wells Fargo & Company upped their price target on shares of Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, January 20th. Citizens Jmp increased their price objective on shares of Rhythm Pharmaceuticals from $141.00 to $167.00 and gave the stock a "market outperform" rating in a research report on Friday, December 12th. Finally, TD Cowen restated a "buy" rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $131.50.
Get Our Latest Stock Report on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals News Roundup
Here are the key news stories impacting Rhythm Pharmaceuticals this week:
- Positive Sentiment: RBC Capital initiated coverage with an "outperform" rating, providing fresh institutional attention and a formal buy-style endorsement that can support the stock. RBC initiates coverage
- Positive Sentiment: Coverage and analyst target upgrades cited by MarketBeat (higher price targets from Wells Fargo, Citizens, Morgan Stanley and others) reinforce a bullish consensus and provide further upside expectations. MarketBeat analyst roundup
- Positive Sentiment: A recent Yahoo Finance piece highlights shifting fundamentals as Imcivree revenue ramps and management updates targets — an operational narrative that supports medium-term revenue growth if execution continues. Imcivree revenue and targets
- Neutral Sentiment: Zacks published two items: an upgrade from "strong sell" to "hold" (reduces downside perception) and a note that RYTM looks positioned to beat upcoming earnings estimates — both are watchpoints but not definitive catalysts until results arrive. Zacks coverage and earnings outlook
- Negative Sentiment: CFO Hunter C. Smith sold shares (4,385 shares at about $101.26) in a transaction disclosed in SEC filings. Insider sales often trigger near-term selling pressure or investor concern even when amounts are a small percentage of total holdings. CFO sale disclosure
Rhythm Pharmaceuticals Company Profile
(
Get Free Report)
Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company's research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.
The company's lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
